Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients With Relapsed Immune Thrombocytopenic Purpura

Trial Profile

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients With Relapsed Immune Thrombocytopenic Purpura

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs PRN 1008 (Primary)
  • Indications Idiopathic thrombocytopenic purpura
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Principia Biopharma
  • Most Recent Events

    • 30 Oct 2018 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
    • 17 Jun 2018 Clinical profile of the PRN1008 presented at the 23rd Congress of the European Haematology Association
    • 15 Jan 2018 New source identified and integrated ( NCT03395210; ClinicalTrials.gov: US National Institutes of Health).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top